Linker Information

General Information of This Linker

Each Antibody-drug Conjugate Related to This Linker

Full Information of The Activity Data of The ADC(s) Related to This Linker

ADC-2-62-2 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	86.30%	Low HER2 expression (HER2 +)
Method Description	Seeding cells (Capan-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	94.20%	Moderate HER2 expression (HER2 ++)
Method Description	Seeding cells (JIMT-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.07 nM	Moderate HER2 expression (HER2 ++)
Method Description	Seeding cells (JIMT-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.29 nM	Low HER2 expression (HER2 +)
Method Description	Seeding cells (Capan-1) into 96-well plate, at 2E3 cell per well (80 uL/well). Overnight incubation.
In Vitro Model	Pancreatic ductal adenocarcinoma	Capan-1 cells		CVCL_0237

References

Ref 1	Antibody drug conjugates; 2023-07-06.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.